Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bausch Health Americas, Inc.
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject was randomized into Study 20090062 and completed the week 16 evaluation.
You may not be if
Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was considered possibly related to IP.
Subject experienced an adverse event in Study 20090062 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject.
